P1224: Patient-Derived Xenograft (Pdx) Is a Useful Tool for Evaluating 5-Azacytidine Sensitivity in TFH Lymphomas

Abstract

Background:TFH lymphomas (TFH PTCL) constitute the most frequent non-cutaneous PTCL entity and are characterized by chemoresistance and a poor prognosis. The main obstacles in therapeutic innovations are the rarity of the disease, the difficulty of diagnosis, and the lack of relevant in vitro/in vivo models which make preclinical studies laborious to perform. 5-azacytidine is a hypomethylating agent associated with prolonged survival (Dupuis et al. ASH2022) in relapsed or refractory TFH PTCL patients, but biomarkers of response and synergistic therapeutic combinations are unknown. Patient-Derived Xenograft (PDX) mouse model allow performing preclinical studies in various cancers, but data on TFH PTCL PDX, and how they recapitulate the patient sensitivity to the drug are limited.